Know Cancer

or
forgot password


N/A
20 Years
80 Years
Not Enrolling
Both
Left-sided Pancreatic Cancer, Ductal Adenocarcinoma

Thank you

Trial Information


Inclusion Criteria:



1. Ductal adenocarcinoma

2. Age ≥20 and ≤80

3. General performance status: the Karnofsky score> 70% or ECOG 0-1

4. Potentially Curative resection

5. Tumor size < 3cm

6. Pancreatic cancer located on neck or body portion

7. No invasion to spleen or spleen hilum

8. No combined resection except Lt. adrenal gland

9. Distance more than 5cm (≥5cm) between tumor lateral margin and spleen hilum

Exclusion Criteria:

1. Unresectable or locally advanced, metastatic case

2. Patients who do not want surgery

3. ASA (American society of anesthesiologists' physical status classification) score: ≥3

4. Patients with drug or alcohol addiction

5. Patients showing low compliance

6. Patients who not want to involve the clinical trial

7. Patients who are unable to read or understand the informed consent, sign a consent
form (eg, mental retardation, blindness, illiteracy, foreign, etc.)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Bleeding amount

Outcome Time Frame:

5 hours

Safety Issue:

Yes

Authority:

South Korea: Korea Food and Drug Administration (KFDA)

Study ID:

4-2013-0138

NCT ID:

NCT01875198

Start Date:

June 2013

Completion Date:

December 2017

Related Keywords:

  • Left-sided Pancreatic Cancer
  • Ductal Adenocarcinoma
  • Splenectomy;
  • Spleen-preserving
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Pancreatic Neoplasms
  • Carcinoma, Ductal, Breast

Name

Location